Skip to main content

Table 3 The prevalence of antimicrobial drug resistance among Klebsiella pneumoniae isolates according to individual studies

From: Klebsiella pneumoniae: an increasing threat to public health

ReferencesNAMKATMCAZCIPCOLCTXFEPGENIPMLVXMEMSXT
Liu et al. [30]106334910649092331064910616
Tian et al. [39]170991611701075170105163105162139
Zhao et al. [40]63486162595850625663
Meng et al. [41]1424589786781696042
Kim et al. [42]579139141131
Xu et al. [43]30162926282423
Guo et al. [44]820325684323407741846005288746514684765357
Dong et al. [29]52347528051374644947
Cha et al. [45]5453515234137
Mitra et al. [52]5545505253522949
Gautam et al. [53]3041091591158157155103120
Mansury et al. [54]386191664
Heidary et al. [55]117407573577512828
Ma et al. [56]760568519
Sum 301249944859485918656133825064156329715635781
Rate (%) 40.873.375.759.82.979.272.65865.654.162.758.2
  1. AMK, amikacin; ATM, aztreonam; CAZ, ceftazidime; CIP, ciprofloxacin; COL, colistin; CTX, cefotaxime; FEP, cefepime; GEN, gentamicin; IPM, imipenem; LVX, levofloxacin; MEM, meropenem; SXT, trimethoprim-sulfamethoxazole